Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite removal from the source of extrinsic raltegra...
Saved in:
Main Authors: | Jos Lommerse (Author), Diana Clarke (Author), Thomas Kerbusch (Author), Henri Merdjan (Author), Han Witjes (Author), Hedy Teppler (Author), Mark Mirochnick (Author), Edward P. Acosta (Author), Larissa Wenning (Author), Sharon Nachman (Author), Anne Chain (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
by: Larson KB, et al.
Published: (2013) -
Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers' and caregivers' perspectives
by: Angela Mushavi, et al.
Published: (2022) -
Physiologically Based Pharmacokinetic Modelling of UGT Substrate Drugs Lamotrigine and Raltegravir during Pregnancy
by: Monika Berezowska, et al.
Published: (2024) -
Raltegravir in the management of HIV-infected patients
by: Hans-Jürgen Stellbrink
Published: (2008) -
Raltegravir: first in class HIV integrase inhibitor
by: Zelalem Temesgen, et al.
Published: (2008)